Telix Doses First U.S. Patient in Phase 3 Prostate Cancer Imaging Trial

Event summary

  • First U.S. patient dosed in BiPASS Phase 3 trial for prostate cancer diagnosis.
  • Study evaluates Telix’s Illuccix and Gozellix PSMA-PET imaging agents.
  • Trial aims to enroll 250 patients across the U.S. and Australia.
  • Objective is to reduce unnecessary biopsies by improving diagnostic accuracy.

The big picture

Telix’s BiPASS trial targets a significant unmet need in prostate cancer diagnosis, where up to 75% of biopsies are negative. Success could validate non-invasive imaging as a standard, reducing patient stress and healthcare costs. The study aligns with broader trends toward precision medicine and minimizing invasive procedures.

What we're watching

Regulatory Pathway
Whether BiPASS success could lead to marketing authorization for 68Ga-PSMA-PET in pre-biopsy settings.
Market Expansion
The pace at which Telix can expand access to precision imaging for prostate cancer diagnosis.
Clinical Validation
How BiPASS results compare to prior PRIMARY studies in defining or ruling out prostate cancer.

Related topics

Pharmaceuticals